Is CGEM or ARTV more profitable?

Cullinan Therapeutics' return on equity of -52.89% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -52.89% -48.18% Artiva Biotherapeutics N/A -83.31% -70.63%

Does the media favor CGEM or ARTV?

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 6 mentions for Cullinan Therapeutics and 5 mentions for Artiva Biotherapeutics. Cullinan Therapeutics' average media sentiment score of 0.16 beat Artiva Biotherapeutics' score of -0.57 indicating that Cullinan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Artiva Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Is FBRX or ARTV more profitable?

Artiva Biotherapeutics' return on equity of -83.31% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -106.17% -85.50% Artiva Biotherapeutics N/A -83.31% -70.63%

Does the media favor FBRX or ARTV?

In the previous week, Forte Biosciences had 1 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 6 mentions for Forte Biosciences and 5 mentions for Artiva Biotherapeutics. Forte Biosciences' average media sentiment score of 0.64 beat Artiva Biotherapeutics' score of -0.57 indicating that Forte Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artiva Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Is ARTV or JBIO more profitable?

Jade Biosciences' return on equity of -51.34% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -83.31% -70.63% Jade Biosciences N/A -51.34% -47.32%

Does the media prefer ARTV or JBIO?

In the previous week, Artiva Biotherapeutics had 1 more articles in the media than Jade Biosciences. MarketBeat recorded 5 mentions for Artiva Biotherapeutics and 4 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.12 beat Artiva Biotherapeutics' score of -0.57 indicating that Jade Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Jade Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CVAC or ARTV?

Artiva Biotherapeutics has a consensus price target of $39.00, indicating a potential upside of 248.18%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Artiva Biotherapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Artiva Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83

Is OLMA or ARTV more profitable?

Olema Pharmaceuticals' return on equity of -46.00% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -46.00% -41.22% Artiva Biotherapeutics N/A -83.31% -70.63%

Does the media prefer OLMA or ARTV?

In the previous week, Artiva Biotherapeutics had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 5 mentions for Artiva Biotherapeutics and 4 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.58 beat Artiva Biotherapeutics' score of -0.57 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artiva Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Artiva Biotherapeutics (ARTV) Competitors

$11.17 -0.10 (-0.85%)

As of 12:24 PM Eastern

Compare

ARTV vs. CGEM, FBRX, JBIO, CVAC, and OLMA

Should you buy Artiva Biotherapeutics stock or one of its competitors? MarketBeat compares Artiva Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Artiva Biotherapeutics include Cullinan Therapeutics (CGEM), Forte Biosciences (FBRX), Jade Biosciences (JBIO), CureVac (CVAC), and Olema Pharmaceuticals (OLMA). These companies are all part of the "biotechnology" industry.

How does Artiva Biotherapeutics compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

Cullinan Therapeutics' return on equity of -52.89% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Artiva Biotherapeutics	N/A	-83.31%	-70.63%

Artiva Biotherapeutics has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Artiva Biotherapeutics	$250K	1,107.55	-$83.86M	-$3.30	N/A

86.3% of Cullinan Therapeutics shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cullinan Therapeutics currently has a consensus price target of $32.14, suggesting a potential upside of 77.65%. Artiva Biotherapeutics has a consensus price target of $39.00, suggesting a potential upside of 248.18%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 6 mentions for Cullinan Therapeutics and 5 mentions for Artiva Biotherapeutics. Cullinan Therapeutics' average media sentiment score of 0.16 beat Artiva Biotherapeutics' score of -0.57 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Artiva Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Cullinan Therapeutics has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market.

Summary

Cullinan Therapeutics beats Artiva Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Artiva Biotherapeutics' return on equity of -83.31% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
Artiva Biotherapeutics	N/A	-83.31%	-70.63%

Forte Biosciences presently has a consensus price target of $72.50, suggesting a potential downside of 5.62%. Artiva Biotherapeutics has a consensus price target of $39.00, suggesting a potential upside of 248.18%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Forte Biosciences has a beta of 2.6, indicating that its share price is 160% more volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market.

In the previous week, Forte Biosciences had 1 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 6 mentions for Forte Biosciences and 5 mentions for Artiva Biotherapeutics. Forte Biosciences' average media sentiment score of 0.64 beat Artiva Biotherapeutics' score of -0.57 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Artiva Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

77.6% of Forte Biosciences shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Forte Biosciences has higher earnings, but lower revenue than Artiva Biotherapeutics. Forte Biosciences is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
Artiva Biotherapeutics	$250K	1,107.55	-$83.86M	-$3.30	N/A

Summary

Artiva Biotherapeutics beats Forte Biosciences on 9 of the 15 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Jade Biosciences?

Artiva Biotherapeutics (NASDAQ:ARTV) and Jade Biosciences (NASDAQ:JBIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Artiva Biotherapeutics has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Artiva Biotherapeutics currently has a consensus target price of $39.00, indicating a potential upside of 248.18%. Jade Biosciences has a consensus target price of $51.57, indicating a potential upside of 130.59%. Given Artiva Biotherapeutics' higher possible upside, research analysts plainly believe Artiva Biotherapeutics is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Jade Biosciences' return on equity of -51.34% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-83.31%	-70.63%
Jade Biosciences	N/A	-51.34%	-47.32%

In the previous week, Artiva Biotherapeutics had 1 more articles in the media than Jade Biosciences. MarketBeat recorded 5 mentions for Artiva Biotherapeutics and 4 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.12 beat Artiva Biotherapeutics' score of -0.57 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Jade Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Artiva Biotherapeutics has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	1,107.55	-$83.86M	-$3.30	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Summary

Jade Biosciences beats Artiva Biotherapeutics on 7 of the 13 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to CureVac?

CureVac (NASDAQ:CVAC) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

CureVac has higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Artiva Biotherapeutics	$250K	1,107.55	-$83.86M	-$3.30	N/A

Artiva Biotherapeutics has a consensus price target of $39.00, indicating a potential upside of 248.18%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Artiva Biotherapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

CureVac has a net margin of 199.92% compared to Artiva Biotherapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Artiva Biotherapeutics	N/A	-83.31%	-70.63%

17.3% of CureVac shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Artiva Biotherapeutics had 5 more articles in the media than CureVac. MarketBeat recorded 5 mentions for Artiva Biotherapeutics and 0 mentions for CureVac. CureVac's average media sentiment score of 0.00 beat Artiva Biotherapeutics' score of -0.57 indicating that CureVac is being referred to more favorably in the media.

Company	Overall Sentiment
CureVac	Neutral
Artiva Biotherapeutics	Negative

CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market.

Summary

CureVac beats Artiva Biotherapeutics on 10 of the 17 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

In the previous week, Artiva Biotherapeutics had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 5 mentions for Artiva Biotherapeutics and 4 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.58 beat Artiva Biotherapeutics' score of -0.57 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Artiva Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Olema Pharmaceuticals' return on equity of -46.00% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Artiva Biotherapeutics	N/A	-83.31%	-70.63%

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Artiva Biotherapeutics has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Artiva Biotherapeutics	$250K	1,107.55	-$83.86M	-$3.30	N/A

Olema Pharmaceuticals has a beta of 2.03, suggesting that its share price is 103% more volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market.

Olema Pharmaceuticals currently has a consensus price target of $44.10, suggesting a potential upside of 267.19%. Artiva Biotherapeutics has a consensus price target of $39.00, suggesting a potential upside of 248.18%. Given Olema Pharmaceuticals' higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Artiva Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Olema Pharmaceuticals beats Artiva Biotherapeutics on 8 of the 15 factors compared between the two stocks.

Get Artiva Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARTV vs. The Competition

Export

Metric	Artiva Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$277.21M	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-3.40	9.06	269.91	24.87
Price / Sales	1,107.55	1,278.42	654.69	108.21
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	2.50	17.97	11.40	6.45
Net Income	-$83.86M	-$13.25M	$3.45B	$347.50M
7 Day Performance	4.10%	5.58%	3.66%	3.77%
1 Month Performance	16.19%	-1.60%	-0.49%	-0.40%
1 Year Performance	305.83%	61.32%	77.51%	23.55%

Artiva Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARTV Artiva Biotherapeutics	2.7705 of 5 stars	$11.17 -0.9%	$39.00 +249.0%	+308.3%	$276.62M	$250K	N/A	81	Earnings Report Analyst Upgrade
CGEM Cullinan Therapeutics	2.6721 of 5 stars	$17.55 +8.0%	$32.14 +83.2%	+142.9%	$1.08B	N/A	N/A	30	Earnings Report
FBRX Forte Biosciences	1.407 of 5 stars	$76.56 -0.1%	$72.50 -5.3%	+654.3%	$1.06B	N/A	N/A	5	Upcoming Earnings
JBIO Jade Biosciences	3.2935 of 5 stars	$21.35 +11.5%	$51.57 +141.6%	+193.2%	$1.05B	N/A	N/A	20	Positive News Earnings Report High Trading Volume
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARTV) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artiva Biotherapeutics (ARTV) Competitors

ARTV vs. CGEM, FBRX, JBIO, CVAC, and OLMA

How does Artiva Biotherapeutics compare to Cullinan Therapeutics?

Summary

How does Artiva Biotherapeutics compare to Forte Biosciences?

Summary

How does Artiva Biotherapeutics compare to Jade Biosciences?

Summary

How does Artiva Biotherapeutics compare to CureVac?

Summary

How does Artiva Biotherapeutics compare to Olema Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTV vs. The Competition

Artiva Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artiva Biotherapeutics (ARTV) Competitors

ARTV vs. CGEM, FBRX, JBIO, CVAC, and OLMA

How does Artiva Biotherapeutics compare to Cullinan Therapeutics?

Is CGEM or ARTV more profitable?

Which has higher valuation & earnings, CGEM or ARTV?

Do insiders and institutionals hold more shares of CGEM or ARTV?

Do analysts prefer CGEM or ARTV?

Does the media favor CGEM or ARTV?

Which has more volatility & risk, CGEM or ARTV?

Summary

How does Artiva Biotherapeutics compare to Forte Biosciences?

Is FBRX or ARTV more profitable?

Do analysts rate FBRX or ARTV?

Which has more risk & volatility, FBRX or ARTV?

Does the media favor FBRX or ARTV?

Do insiders & institutionals hold more shares of FBRX or ARTV?

Which has higher earnings & valuation, FBRX or ARTV?

Summary

How does Artiva Biotherapeutics compare to Jade Biosciences?

Which has more risk and volatility, ARTV or JBIO?

Do analysts prefer ARTV or JBIO?

Is ARTV or JBIO more profitable?

Does the media prefer ARTV or JBIO?

Which has stronger earnings and valuation, ARTV or JBIO?

Summary

How does Artiva Biotherapeutics compare to CureVac?

Which has stronger earnings and valuation, CVAC or ARTV?

Do analysts prefer CVAC or ARTV?

Is CVAC or ARTV more profitable?

Do insiders & institutionals believe in CVAC or ARTV?

Does the media favor CVAC or ARTV?

Which has more risk and volatility, CVAC or ARTV?

Summary

How does Artiva Biotherapeutics compare to Olema Pharmaceuticals?

Does the media prefer OLMA or ARTV?

Is OLMA or ARTV more profitable?

Do institutionals and insiders have more ownership in OLMA or ARTV?

Which has stronger earnings and valuation, OLMA or ARTV?

Which has more risk and volatility, OLMA or ARTV?

Do analysts rate OLMA or ARTV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTV vs. The Competition

Artiva Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools